How antipsychotics work - From receptors to reality

NeuroRx

Volumn 3, Issue 1, 2006, Pages 10-21

  Kapur, Shitij ^a,b   Agid, Ofer ^a,b   Mizrahi, Romina ^a,b   Li, Ming ^a,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Antipsychotics; D2 3 receptors; Dopamine; Salience; Schizophrenia

Indexed keywords

ANXIOLYTIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BARBITURIC ACID DERIVATIVE; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; HALOPERIDOL; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN REGION; CLINICAL TRIAL; CORPUS STRIATUM; DELUSION; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC TRANSMISSION; DRUG DESIGN; DRUG MECHANISM; DRUG SCREENING; HALLUCINATION; HUMAN; LEARNING; MOTIVATION; NERVE CELL PLASTICITY; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; PARANOIA; PATIENT CARE; PHENOMENOLOGY; PSYCHOSIS; REVIEW; STIMULUS RESPONSE; SYMPTOMATOLOGY;

EID: 33244462829     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1016/j.nurx.2005.12.003     Document Type: Article

References (171)

1. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160:13-23, 2003.
2. Kapur S. How antipsychotics become anti-"psychotic"-from dopamine to salience to psychosis. Trends Pharmacol Sci 25:402-406, 2004.
3. Wise RA, Spindler J, deWit H, Gerberg GJ. Neuroleptic-induced "anhedonia" in rats: pimozide blocks reward quality of food. Science 201:262-264, 1978.
4. Salamone JD. The involvement of nucleus accumbens dopamine in appetitive and aversive motivation. Behav Brain Res 61:117-133, 1994.
5. Wightman RM, Robinson DL. Transient changes in mesolimbic dopamine and their association with 'reward.' J Neurochem 82:721-735, 2002.
6. Fibiger HC, Phillips AG. Reward, motivation, cognition: psychobiology of mesotelencephalic dopamine systems. In: Handbook of physiology-the nervous system (Mountcastle VB, ed), Vol 4, pp 647-675. Bethesda, MD: American Physiological Society, 1986.
7. Schultz W. Getting formal with dopamine and reward. Neuron 36:241-263, 2002.
8. Schultz W. Reward signaling by dopamine neurons. Neuroscientist 7:293-302, 2001.
9. Phillips PEM, Stuber GD, Heien MLAV, Wightman RM, Carelli RM. Subsecond dopamine release promotes cocaine seeking. Nature 422:614-618, 2003.
10. Berridge KC. Pleasure, pain, desire and dread: hidden core processes of emotion. In: Well being: the foundations of hedonic psychology (Kahneman D, Diener E, Schwarz N, eds), pp 525-557. New York: Russel Sage Foundation, 1999.
11. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28:309-369, 1998.
12. Wise RA. Dopamine, learning and motivation. Nat Rev Neurosci 5:483-494, 2004.
13. Mogenson GJ, Jones DL, Yim CY. From motivation to action: functional interface between the limbic system and the motor system. Prog Neurobiol 14:69-97, 1980.
14. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474-1486, 1991.
15. Seeman P, Kapur S. Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci USA 97:7673-7675, 2000.
16. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 7:S1-S5, 2004.
17. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10:40-68, 2005.
18. Laruelle M, Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 13:358-371, 1999.
19. Shizgal P. Neural basis of utility estimation. Curr Opin Neurobiol 7:198-208, 1997.
20. Heinz A. Anhedonia-a general nosology surmounting correlate of a dysfunctional dopaminergic reward system? Nervenarzt 70:391-398, 1999.
21. Lewis DA, Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 25:409-432, 2002.
22. Roberts G. The origins of delusion [see comments]. Br J Psychiatry 161:298-308, 1992.
23. Bowers MB Jr. Pathogenesis of acute schizophrenic psychosis. An experimental approach. Arch Gen Psychiatry 19:348-355, 1968.
24. Clody DE, Carlton PL. Stimulus efficacy, chlorpromazine, and schizophrenia. Psychopharmacology 69:127-131, 1980.
25. Miller R. The time course of neuroleptic therapy for psychosis: role of learning processes and implications for concepts of psychotic illness. Psychopharmacology 92:405-415, 1987.
26. Miller R. Hyperactivity of associations in psychosis. Aust N Z J Psychiatry 23:241-248, 1989.
27. Chouinard G, Miller RA. Rating scale for psychotic symptoms (RSPS) part I: theoretical principles and subscale 1: perception symptoms (illusions and hallucinations). Schizophr Res 38:101-122, 1999.
28. Gerlach J, Larsen EB. Subjective experience and mental side-effects of antipsychotic treatment. Acta Psychiatr Scand Suppl 395:113-117, 1999.
29. Sanchez-Gonzalez MA, Garcia-Cabezas MA, Rico B, Cavada C. The primate thalamus is a key target for brain dopamine. J Neurosci 25:6076-6083, 2005.
30. Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res 24:165-205, 2004.
31. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev 78:189-225, 1998.
32. Carlsson A, Lindquist M. Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140-144, 1963.
33. van Rossum J. The significance of dopamine-receptor blockade for the action of neuroleptic drugs. In: Neuropsychopharmacology, Proceedings of the 5th Collegium Internationale Neuropsychopharmacologicum (Brill H, Cole J, Deniker P, Hippius H, Bradley P, eds), pp 321-329. Amsterdam: Excerpta Medica, 1967.
34. Seeman P, Chau-Wong M, Tedesco J, Wong K. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci USA 72:4376-4380, 1975.
35. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-719, 1976.
36. Creese I, Burt, DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483, 1976.
37. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 277:93-96, 1979.
38. Farde L, Wiesel FA, Halldin C, Sedvall G. PET-determination of central D1- and D2-dopamine receptor occupancy in neuroleptic treated schizophrenics. In: Clinical efficacy of positron emission tomography (Heiss W-D, Pawlick G, Herholz K, Wienhard K, eds), pp 213-219. Dordrecht, Holland: Martinus Nijhoff Publishers, 1987.
39. Nordstrom AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects-a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235, 1993.
40. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520, 2000.
41. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27:1081-1090, 2003.
42. Frankle WG, Gil R, Hackett E, et al. Occupancy of dopamine D-2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. Psychopharmacology 175:473-480, 2004.
43. Tauscher J, Kapur S. Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies. CNS Drugs 15:671-678, 2001.
44. Nyberg S, Nilsson U, Okubo Y, Halldin C, Farde L. Implications of brain imaging for the management of schizophrenia. Int Clin Psychopharmacol 13[Suppl 3]:S15-S20, 1998.
45. Nordstrom AL, Farde L, Nyberg S, et al. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients [see comments]. Am J Psychiatry 152:1444-1449, 1995.
46. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57:553-559, 2000.
47. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158:360-369, 2001.
48. Yokoi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27:248-259, 2002.
49. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27-38, 2002.
50. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389, 2002.
51. Karlsson P, Smith L, Farde L, et al. Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology (Berl) 121:309-316, 1995.
52. Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544, 1992.
53. Den Boer JA, van Megen HJ, Fleischhacker WW, et al. Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. Psychopharmacology (Berl) 121:317-322, 1995.
54. de Beaurepaire R, Labelle A, Naber D, Jones BD, Barnes TR. An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states. Psychopharmacology (Berl) 121:323-327, 1995.
55. Karle J, Clemmesen L, Hansen L, et al. NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia [letter]. Psychopharmacology (Berl) 121:328-329, 1995.
56. Tauscher J, Hussain T, Agid O, et al. Equivalent occupancy of dopamine D-1 and D-2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry 161:1620-1625, 2004.
57. Abi-Dargham A, Moore H. Prefrontal DA transmission at D-1 receptors and the pathology of schizophrenia. Neuroscientist 9:404-416, 2003
58. Joyce J. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Therapeut 90:231-259, 2001
59. Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today 10:917-925, 2005.
60. Ralph RJ, Varty GB, Kelly MA, et al. The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J Neurosci 19:4627-4633, 1999.
61. Remington G, Kapur S. SB-277011 GlaxoSmithKline. Curr Opin Investig Drugs 2:946-949, 2001.
62. Lecrubier Y. Partial D3 receptor agonist in schizophrenia. J Euro College Neuropsychopharmacol 13:S167-S168, 2003.
63. Lahti AC, Weiler M., Carlsson A, Tamminga CA. Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia. J Neural Transm 105:719-734, 1998.
64. Seeman P, Vantol HHM. Dopamine D4-like receptor elevation in schizophrenia: Cloned D2 and D4 receptors cannot be discriminated by raclopride competition against [H-3]nemonapride. J Neurochem 64:1413-1415, 1995.
65. Seeman P, Guan HC, VanTol, HH. Dopamine D4 receptors elevated in schizophrenia [see comments]. Nature 365:441-445, 1993.
66. Seeman P. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7:261-284, 1992.
67. Corrigan MH, Gallen CC, Bonura ML, Merchant KM. Effectiveness of the selective D-4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. Biol Psychiatry 55:445-451, 2004.
68. Bristow LJ, Kramer MS, Kulagowski J, et al. Schizophrenia and L-745, 870, a novel dopamine D4 receptor antagonist. Trends Pharmacol Sci 18:186-188, 1997.
69. Truffinet P, Tamminga CA, Fabre LF, et al. Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. Am J Psychiatry 156:419-425, 1999
70. Seeman P, Ulpian C. Neuroleptics have identical potencies in human brain limbic and putamen regions. Eur J Pharmacol 94:145-148, 1983.
71. Leysen JE, Gommeren W, Mertens J, et al. Comparison of in vitro binding properties of a series of dopamine antagonists and agonists for cloned human dopamine D2S and D2L receptors and for D2 receptors in rat striatal and mesolimbic tissues, using [125I] 2′-iodospiperone. Psychopharmacology 110:27-36, 1993.
72. Usiello A, Baik JH, Rouge-Pont F, et al. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408:199-203, 2000.
73. Centonze D, Usiello A, Gubellini P, et al. Dopamine D2 receptor-mediated inhibition of dopaminergic neurons in mice lacking D2L receptors. Neuropsychopharmacology 27:723-726, 2002.
74. Bressan RA, Erlandsson K, Spencer EP, Ell PJ, Pilowsky LS. Prolactinemia is uncoupled from central D-2/D-3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacology 175:367-373, 2004.
75. Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother 3:1381-1391, 2002.
76. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57-73, 1996.
77. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101, 1998.
78. Kapur S, Langlois X, Vinken P, et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 302:1129-1134, 2002.
79. Robertson GS, Fibiger HC. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46:315-328, 1992.
80. Robertson GS, Matsumura H, Fibiger HC. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271:1058-1066, 1994.
81. Grace AA, Bunney BS, Moore H, Todd CL. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci 20:31-37, 1997.
82. Skarsfeldt T. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 281:289-294, 1995.
83. Skarsfeldt T. Differential effects after repeated treatment with haloperidol, clozapine, thioridazine and tefludazine on SNC and VTA dopamine neurones in rats. Life Sci 42:1037-1044, 1988.
84. Fibiger HC, Phillips AG. Mesocorticolimbic dopamine systems and reward. Ann NY Acad Sci 537:206-215, 1988.
85. Ettenberg A. Dopamine, neuroleptics and reinforced behavior. Neurosci Biobehav Rev 13:105-111, 1989.
86. Wise RA. Brain reward circuitry: insights from unsensed incentives. Neuron 36:229-240, 2002.
87. Bigliani V, Mulligan RS, Acton PD, et al. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a. Psychopharmacology (Berl) 150:131-140, 2000.
88. Xiberas X, Martinot JL, Mallet L, et al. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 179:503-508, 2001.
89. Olsson H, Farde L. Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy-a simulation study based on experimental data. Neuroimage 14:936-945, 2001.
90. Talvik M, Nordstrom AL, Nyberg S, et al. No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. Am J Psychiatry 158:926-930, 2001.
91. Yasuno F, Suhara T, Okubo Y, et al. Dose relationship of limbic-cortical D2-dopamine receptor occupancy with risperidone. Psychopharmacology (Berl) 154:112-114, 2001.
92. Kessler RM, Ansari MS, Riccardi P, et al. Occupancy of striatal and extrastriatal dopamine D(2)/D(3) receptors by Olanzapine and Haloperidol. Neuropsychopharmacology 30:2283-2289, 2005.
93. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 7:317-321, 2002.
94. Agid O, Mamo D, Zipursky RB, et al. Differentiating the roles of striatal vs. extrastriatal dopamine D2 receptors in antipsychotic response-a PET study. Schizophr Bull 31:442, 2005.
95. Gelder MG, Løpez-Ibor JJ, Andreasen N. New Oxford textbook of psychiatry. New York: Oxford University Press, Inc., 2000.
96. Grace AA, Bunney BS. Electrophysiological properties of mid-brain dopamine neurons. In: Psychopharmacology, pp 163-177. New York: Raven Press, 1995.
97. Marder SV, Van-Kammen DP. Dopamine receptor antagonists. In: Comprehensive textbook of psychiatry (Kaplan HS, BJ, eds), Vol 2, pp 2356-2377. Baltimore: Lippincott Williams & Wilkins, 2000.
98. Van-Kammen DP, SR. Serotonin dopamine antagonists. In: Comprehensive textbook of psychiatry (Kaplan HI, Sadock BJ, eds), Vol 2, pp 2455-2473. Baltimore: Lippincot, Williams & Wilkins, 2000.
99. Brodie MS, Bunney EB. Serotonin potentiates dopamine inhibition of ventral tegmental area neurons in vitro. J Neurophysiol 76:2077-2082, 1996.
100. Grace AA. The depolarization block hypothesis of neuroleptic action: implications for the etiology and treatment of schizophrenia. J Neural Transm Suppl 36:91-131, 1992.
101. Grace AA. Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. J Neural Transm Gen Sect 91:111-134, 1993.
102. Grace AA, Bunney BS. Induction of depolarization block in midbrain dopamine neurons by repeated administration of haloperidol: analysis using in vivo intracellular recording. J Pharmacol Exp Ther 238:1092-1100, 1986.
103. Harden DG, Grace AA. Activation of dopamine cell firing by repeated L-DOPA administration to dopamine-depleted rats: its potential role in mediating the therapeutic response to L-DOPA treatment. J Neurosci 15:6157-6166, 1995.
104. Hollerman JR, Abercrombie E, Grace AA. Electrophysiological, biochemical, and behavioral studies of acute haloperidol-induced depolarization block of nigral dopamine neurons. Neuroscience 47:589-601, 1992.
105. Hollerman JR, Grace AA. Acute haloperidol administration induces depolarization block of nigral dopamine neurons in rats after partial dopamine lesions. Neurosci Lett 96:82-88, 1989.
106. Holleraian JR, Grace AA. Subthalamic nucleus cell firing in the 6-OHDA-treated rat: basal activity and response to haloperidol. Brain Res 590:291-299, 1992.
107. Moore H, Todd CL, Grace AA. Striatal extracellular dopamine levels in rats with haloperidol-induced depolarization block of substantia nigra dopamine neurons. J Neurosci 18:5068-5077, 1998.
108. Onn SP, Grace AA. Repeated treatment with haloperidol and clozapine exerts differential effects on dye coupling between neurons in subregions of striatum and nucleus accumbens. J Neurosci 15:7024-7036, 1995.
109. Pucak ML, Grace AA. Evidence that systemically administered dopamine antagonists activate dopamine neuron firing primarily by blockade of somatodendritic autoreceptors. J Pharmacol Exp Ther 271:1181-1192, 1994.
110. Nordstrom AL, Farde L, Halldin C. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl) 106:433-438, 1992.
111. Baldessarini RJ, Cohen BM, Teicher M. Pharmacologic treatment. In: Schizophrenia: treatment of acute psychotic episodes (Levy ST, Ninan PT, eds), pp 61-118. Washington, DC: American Psychiatric Press, 1990.
112. Elkes J, Elkes C. Effects of chlorpromazine on the behaviour of chronically overactive psychotic patients. BMJ 4:560-565, 1954.
113. Winkelman NW. Chlorpromazine in the treatment of neuropsychiatric disorders. JAMA 155:18-21, 1954.
114. Delay J, Deniker P, Harl JM, Grasset A. [N-dimethylamino- prophylchlorophenothiazine (4560 RP) therapy of confusional states.]. Ann Med Psychol (Paris) 110:398-403, 1952.
115. Delay J, Deniker P, Harl JM. [Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP).]. Ann Med Psychol (Paris) 110:112-117, 1952.
116. Stern RG, Kahn RS, Davidson M, Nora RM, Davis KL. Early response to clozapine in schizophrenia. Am J Psychiatry 151:1817-1818, 1994.
117. Stern RG, Kahn RS, Harvey PD, et al. Early response to haloperidol treatment in chronic schizophrenia. Schizophr Res 10:165-171, 1993.
118. McDermott BE, Sautter FJ, Garver DL. Heterogeneity of schizophrenia: relationship to latency of neuroleptic response. Psychiatry Res 37:97-103, 1991.
119. Garver DL, Kelly K, Fried KA, Magnusson M, Hirschowitz J. Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias). Psychol Med 18:873-885, 1988.
120. Garver DL, Steinberg JL, McDermott BE, et al. Etiologic heterogeneity of the psychoses: is there a dopamine psychosis? Neuropsychopharmacology 16:191-201, 1997.
121. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 60:1228-1235, 2003.
122. Kapur S, Arenovich T, Agid O, et al. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry 162:939-946, 2005.
123. Leucht S, Busch R, Hamann J, Kissling W, Kane JM. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 57:1543-1549, 2005.
124. Casey JF, Bennett IF, Lindley CJ, et al. Drug therapy in schizophrenia. A controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital, and placebo. Arch Gen Psychiatry 2:210-220, 1960.
125. Casey JF, Lasky JJ, Klett CJ, Hollister LE. Treatment of schizophrenic reactions with phenothiazine derivatives. A comparative study of chlorpromazine, triflupromazine, mepazine, prochlorperazine, perphenazine, and phenobarbital. Am J Psychiatry 117:97-105, 1960.
126. Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 26:121-124, 1993.
127. Johnstone EC, Crow TJ, Frith CD, Carney MW, Price JS. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1:848-851, 1978.
128. Voruganti LN, Awad AG. Personal evaluation of transitions in treatment (PETiT):a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res 56:37-46, 2002.
129. Kampman O, Lehtinen K, Lassila V, et al. Attitudes towards neuroleptic treatment: reliability and validity of the attitudes towards neuroleptic treatment (ANT) questionnaire. Schizophr Res 45:223-234, 2000.
130. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 42:241-247, 2000.
131. Van Putten T, May PR, Marder SR, Wittmann LA. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 38:187-190, 1981.
132. Awad AG, Voruganti LN. Quality of life and new antipsychotics in schizophrenia. Are patients better off? Int J Soc Psychiatry 45:268-275, 1999.
133. Awad AG, Hogan TP, Voruganti LN, Heslegrave RJ. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 10[Suppl 3]:123-132, 1995.
134. Diamond R. Drugs and the quality of life: the patient's point of view. J Clin Psychiatry 46:29-35, 1985.
135. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 22:347-352, 1992.
136. Mizrahi R, Bagby RM, Zipursky RB, Kapur S. How antipsychotics work: the patients' perspective. Prog Neuropsychopharmacol Biol Psychiatry 29:859-864, 2005.
137. Mizrahi R, Bagby R, Remington G, Zipursky R, Kapur S. Understanding how antipsychotics improve psychosis: a multidimensional perspective. Schizophr Bull 31:497, 2005.
138. Abi-Dargham A, Rodenhiser J, Printz D, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97:8104-8109, 2000.
139. Laborit H, Huguenard P. L'hibernation artificielle par moyen pharmacodynamique et physisques. Presse Med 59:1321, 1951.
140. Delay J, Deniker P, Harl JM. [Therapeutic method derived from hiberno-therapy in excitation and agitation states]. Ann Med Psychol (Paris) 110:267-273, 1952.
141. Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol (Copenh) 51:321-329, 1982.
142. Ellenbroek BA., Peeters BW, Honig WM, Cools AR. The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology (Berl) 93:343-348, 1987.
143. Hoffman DC, Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl) 120:128-133, 1995.
144. Weiner I. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl) 169:257-297, 2003.
145. Johansson C, Jackson DM, Zhang J, Svensson L. Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: effects of antipsychotics and other agents in rats. Pharmacol Biochem Behav 52:649-654, 1995.
146. Sams-Dodd F. Effects of dopamine agonists and antagonists on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Psychopharmacology (Berl) 135:182-193, 1998.
147. Lipska BK. Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J Psychiatry Neurosci 29:282-286, 2004.
148. Feldon J, Weiner I. The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli. Biol Psychiatry 29:635-646, 1991.
149. Swerdlow NR, Geyer, MA. Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacol Biochem Behav 44:741-744, 1993.
150. Hiroi N, Graybiel AM. Atypical and typical neuroleptic treatments induce distinct programs of transcription factor expression in the striatum. J Comp Neurol 374:70-83, 1996.
151. Andersen MP, Pouzet B. Effects of acute versus chronic treatment with typical or atypical antipsychotics on d-amphetamine-induced sensorimotor gating deficits in rats. Psychopharmacology (Berl) 156:291-304, 2001.
152. Kilts CD. The changing roles and targets for animal models of schizophrenia. Biol Psychiatry 50:845-855, 2001.
153. Wadenberg ML, Hicks PB. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 23:851-862, 1999.
154. Solomon RL, Kamin LJ, Wynne LC. Traumatic avoidance learning: the outcomes of several extinction procedures with dogs. J Abnormal Social Psychol 48:291-302, 1953.
155. Baum M. Efficacy of response prevention (flooding) in facilitating the extinction of an avoidance response in rats: the effect of overtraining the response. Behav Res Ther 6:197-203, 1968.
156. Reckless G, Natesan S, Parkes J, et al. Dissociation between blockade and functional antagonism of D2 receptors-comparing aripiprazole to other typical and atypical antipsychotics in animal models. Schizophr Bull 31:309, 2005.
157. Wadenberg ML, Kapur S, Soliman A, Jones C, Vaccarino F. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 150:422-429, 2000.
158. Beninger RJ. The role of serotonin and dopamine in learning to avoid aversive stimuli. In: Aversion, avoidance, and anxiety: perspective on aversively motivated behavior (Archer T, Nilsson L, eds), pp 265-284. Hillsdale, NJ: Lawrence Erlbaum Associates, 1989.
159. Li M, Parkes J, Fletcher PJ, Kapur S. Evaluation of the motor initiation hypothesis of APD-induced conditioned avoidance decreases. Pharmacol Blochem Behav 78:811-819, 2004.
160. Li M, Kapur S, Fletcher P. Examining the time course of antipsychotic treatment in schizophrenia using conditioned avoidance responding model. In: Society for Neuroscience, Washington, DC, 2005.
161. Gilbert PL, Harris M, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 52:173-188, 1995.
162. Lieberman JA, Swartz MS, Rosenheck RA, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223, 2005.
163. Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161:780-796, 2004.
164. Blasi G, Bertolino A. Imaging genomics and response to treatment with antipsychotics in schizophrenia. NeuroRx 3:117-130, 2006.
165. Stahl S. Finding what you are not looking for: strategies for developing novel treatments in psychiatry. NeuroRx 3:3-9, 2006.
166. Sanger DJ. The search for novel antipsychotics: pharmacological and molecular targets. Expert Opin Ther Targets 8:631-641, 2004.
167. Beaulieu JM, Sotnikova TD, Marion S, et al. An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261-273, 2005.
168. Bartlett SE, Enquist J, Hopf FW, et al. Dopamine responsiveness is regulated by targeted sorting of D2 receptors. Proc Natl Acad Sci USA 102:11521-11526, 2005.
169. Lee SP, So CH, Rashid AJ, et al. Dopamine D1 and D2 receptor co-activation generates a novel phospholipase C-mediated calcium signal. J Biol Chem 279:35671-35688, 2004.
170. George SR, Ng GY, Lee SP, et al. Blockade of G protein-coupled receptors and the dopamine transporter by a transmembrane domain peptide: Novel strategy for functional inhibition of membrane proteins in vivo. J Pharmacol Exp Ther 307:481-489, 2003.
171. Simon AB, Gorman JM. Advances in the treatment of anxiety: targeting glutamate. NeuroRx 3:57-68, 2006.